Cohance Lifesciences Limited has informed the Exchange about Completion of USFDA Inspection
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The USFDA completed a Good Manufacturing Practices (GMP) inspection at Cohance Lifesciences' Finished Dosage Formulations Manufacturing Facility (FDF Unit-I) in Nacharam, Hyderabad, from August 4 to August 12, 2025. The company received a Form 483 with 6 observations, which it describes as predominantly procedural in nature. Cohance is preparing a comprehensive response to submit to the agency within the required timeframe. The company has assured that it remains committed to maintaining high quality and regulatory compliance standards for its global pharmaceutical supply.
Form 483 observations are common after USFDA inspections and not immediately negative, but 6 observations — even if procedural — may raise short-term investor attention. A timely, satisfactory response is key to avoiding any escalation into a Warning Letter, which could impact US exports and earnings.